This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sørensen, P. S. Articles by Ravnborg, M. Search for Related Content PubMed PubMed Citation Articles by Sørensen, P. S. Articles by Ravnborg, M. Social Bookmarking                         What's this?

A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results

Copenhagen Multiple Sclerosis Clinic, Department of Neurology, Rigshospitalet, and The Danish Magnetic Resonance Center, Copenhagen University Hospital, Copenhagen, Denmark

B. Wanscher

Copenhagen Multiple Sclerosis Clinic, Department of Neurology, Rigshospitalet, and The Danish Magnetic Resonance Center, Copenhagen University Hospital, Copenhagen, Denmark

K. Schreiber

Copenhagen Multiple Sclerosis Clinic, Department of Neurology, Rigshospitalet, and The Danish Magnetic Resonance Center, Copenhagen University Hospital, Copenhagen, Denmark

M. Blinkenberg

Copenhagen Multiple Sclerosis Clinic, Department of Neurology, Rigshospitalet, and The Danish Magnetic Resonance Center, Copenhagen University Hospital, Copenhagen, Denmark

C.V. Jensen

Copenhagen Multiple Sclerosis Clinic, Department of Neurology, Rigshospitalet, and The Danish Magnetic Resonance Center, Copenhagen University Hospital, Copenhagen, Denmark

M. Ravnborg

Copenhagen Multiple Sclerosis Clinic, Department of Neurology, Rigshospitalet, and The Danish Magnetic Resonance Center, Copenhagen University Hospital, Copenhagen, Denmark

We enrolled 25 patients with relapsing-remitting or relapsing progressive multiple sclerosis (MS) in a randomized placebo-controlled double-blind study of intravenous immunoglobulin G (IVIG). IVIG Iglkg daily for 2 days was administered every 4 weeks for 24 weeks. Seventeen patients completed the whole trial, whereas eight patients discontinued the trial; four during IVIG treatment and four on placebo. Of the 17 patients who completed the trial, II had no exacerbations during IVIG treatment compared with only six on placebo (P=0.05). The total number of exacerbations in the IVIG period was I / and in the placebo period 15 (NS), and the number of severe exacerbations requiring treatment with intravenous methylprednisolone was four during treatment with IVIG and six on placebo (NS). The results suggest that IVIG treatment may be of beneft for prevention of exacerbations in patients with relapsing MS.

Key Words: IgG • intravenous immunoglobulins • multiple sclerosis • multiple sclerosis therapy

Multiple Sclerosis, Vol. 3, No. 2, 145-148 (1997)
DOI: 10.1177/135245859700300216


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. S Francis, M. S Freedman, and J. P Antel Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study Multiple Sclerosis, December 1, 1997; 3(6): 370 - 376. [Abstract] [PDF]